Credit: Ludwig Cancer Research
NOVEMBER 23, 2017, New York — A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development. The discovery addresses a longstanding challenge: as many as 40% of large tumors develop resistance to radiotherapy, significantly complicating treatment. Overcoming such resistance could go a long way toward treating tumors, especially those that cause significant discomfort to patients and resist other modes of therapy or cannot be surgically removed.
"It has been known for some time that radiation induces inflammation, and we've shown in our earlier work that it does so through a molecular sensor found in cells known as the stimulator of interferon genes, or STING," says Ralph Weichselbaum, co-director of the Ludwig Center at Chicago, who led the study with Yang-Xin Fu of the UT Southwestern Medical Center. "However, there's a dark side to radiation: after it causes good inflammation–which mounts an immune attack on cancer cells in the irradiated tumor–it causes a bad kind of inflammation that suppresses immune responses."
STING detects DNA fragments inside cells, fragments generated by the damage high energy radiation does to chromosomes. In previous studies, Weichselbaum, Fu and their colleagues showed that STING links the detection of such fragments to the production of immune factors known as type 1 interferons. These factors ultimately boost the activation of killer T cells–immune cells that attack sick and cancerous cells–and cause much of the destruction of tumors associated with radiation therapy.
The researchers hypothesized that this same STING/Type 1 interferon signaling cascade might also account for the resistance tumors develop to extended radiotherapy. They report in the current issue of Nature Communications that this indeed appears to be the case. The immunosuppression, they found, is caused by an influx of particular suppressive immune cells known as monocytic myeloid-derived suppressor cells (M-MDSCs) that are drawn into the tumor due to long-term STING/Type 1 interferon signaling.
Using mouse models of lung and colon tumors, the researchers found that the tumor-infiltrating M-MDSCs express a cell surface receptor known as CCR2, whose ligand–or binding target–is expressed by cells upon STING activation. They then showed that resistance to radiotherapy was significantly reduced in mice engineered to lack CCR2.
To determine whether the effect might be translated into clinical practice, the researchers checked whether it could be reproduced in mice that express CCR2 with the use of antibodies to the receptor. They found it could. Most notably, in both types of mice the destruction of tumors was significantly boosted when the radiation therapy was delivered along with a STING-activating drug and anti-CCR2 antibodies.
"What we did by combining those treatments was to stimulate the immune system while alleviating immune suppression, and that worked best to improve responses to radiotherapy–more than either did alone," says Weichselbaum.
Pharmaceutical companies are developing STING activating drugs for cancer therapy, and one is currently being evaluated in clinical trials in combination with checkpoint blockade–a type of immunotherapy that boosts T cell attack on certain types of tumors. Similarly, antibodies to CCR2 are also being developed as potential immunotherapeutic agents. The current study lays the groundwork for combining these experimental drugs to improve the effects of radiotherapy for a variety of solid tumors.
"What we've shown in this preclinical study is that if you block the influx of these MDSCs, you can, to a large extent, preempt resistance to radiation therapy," says Weichselbaum. "Our current study is of immediate relevance to radiation therapy, but we think it may also have significant implications for chemotherapy and immunotherapy as well."
###
This study was supported by Ludwig Cancer Research, Mr. & Mrs. Vincent Foglia, The Chicago Tumor Institute, The Cancer Research Foundation, the National Cancer Institute, the Science and Technology Commission of Shanghai Municipality and the National Thousand Youth Talents Program.
About Ludwig Cancer Research
Ludwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer research and landmark discovery for more than 40 years. Ludwig combines basic science with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested $2.7 billion in life-changing science through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers. To learn more, visit http://www.ludwigcancerresearch.org.
For further information please contact Rachel Steinhardt, [email protected] or +1-212-450-1582.
Media Contact
Rachel Steinhardt
[email protected]
212-450-1582
@Ludwig_Cancer
http://www.licr.org
